216 related articles for article (PubMed ID: 37442413)
21. Transient overexpression of exogenous APOBEC3A causes C-to-U RNA editing of thousands of genes.
Sharma S; Patnaik SK; Kemer Z; Baysal BE
RNA Biol; 2017 May; 14(5):603-610. PubMed ID: 27149507
[TBL] [Abstract][Full Text] [Related]
22. HPV11 E6 mutation by overexpression of APOBEC3A and effects of interferon-ω on APOBEC3s and HPV11 E6 expression in HPV11.HaCaT cells.
Wang Y; Li X; Song S; Sun Y; Zhang J; Yu C; Chen W
Virol J; 2017 Nov; 14(1):211. PubMed ID: 29100527
[TBL] [Abstract][Full Text] [Related]
23. APOBEC3A cytidine deaminase induces RNA editing in monocytes and macrophages.
Sharma S; Patnaik SK; Taggart RT; Kannisto ED; Enriquez SM; Gollnick P; Baysal BE
Nat Commun; 2015 Apr; 6():6881. PubMed ID: 25898173
[TBL] [Abstract][Full Text] [Related]
24. Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase.
Narvaiza I; Linfesty DC; Greener BN; Hakata Y; Pintel DJ; Logue E; Landau NR; Weitzman MD
PLoS Pathog; 2009 May; 5(5):e1000439. PubMed ID: 19461882
[TBL] [Abstract][Full Text] [Related]
25. Structure-Guided Design of a Potent and Specific Inhibitor against the Genomic Mutator APOBEC3A.
Serrano JC; von Trentini D; Berríos KN; Barka A; Dmochowski IJ; Kohli RM
ACS Chem Biol; 2022 Dec; 17(12):3379-3388. PubMed ID: 36475588
[TBL] [Abstract][Full Text] [Related]
26. APOBEC3A damages the cellular genome during DNA replication.
Green AM; Landry S; Budagyan K; Avgousti DC; Shalhout S; Bhagwat AS; Weitzman MD
Cell Cycle; 2016; 15(7):998-1008. PubMed ID: 26918916
[TBL] [Abstract][Full Text] [Related]
27. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage.
Caval V; Suspène R; Shapira M; Vartanian JP; Wain-Hobson S
Nat Commun; 2014 Oct; 5():5129. PubMed ID: 25298230
[TBL] [Abstract][Full Text] [Related]
28. Exploring ABOBEC3A and APOBEC3B substrate specificity and their role in HPV positive head and neck cancer.
Papini C; Wang Z; Kudalkar SN; Schrank TP; Tang S; Sasaki T; Wu C; Tejada B; Ziegler SJ; Xiong Y; Issaeva N; Yarbrough WG; Anderson KS
iScience; 2022 Oct; 25(10):105077. PubMed ID: 36164654
[TBL] [Abstract][Full Text] [Related]
29. Methylcytosine and normal cytosine deamination by the foreign DNA restriction enzyme APOBEC3A.
Carpenter MA; Li M; Rathore A; Lackey L; Law EK; Land AM; Leonard B; Shandilya SM; Bohn MF; Schiffer CA; Brown WL; Harris RS
J Biol Chem; 2012 Oct; 287(41):34801-8. PubMed ID: 22896697
[TBL] [Abstract][Full Text] [Related]
30. NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity.
Byeon IJ; Ahn J; Mitra M; Byeon CH; Hercík K; Hritz J; Charlton LM; Levin JG; Gronenborn AM
Nat Commun; 2013; 4():1890. PubMed ID: 23695684
[TBL] [Abstract][Full Text] [Related]
31. The implications of APOBEC3-mediated C-to-U RNA editing for human disease.
Van Norden M; Falls Z; Mandloi S; Segal BH; Baysal BE; Samudrala R; Elkin PL
Commun Biol; 2024 May; 7(1):529. PubMed ID: 38704509
[TBL] [Abstract][Full Text] [Related]
32. Murine leukemia virus resists producer cell APOBEC3A by its Glycosylated Gag but not target cell APOBEC3A.
Jaguva Vasudevan AA; Balakrishnan K; Franken A; Krikoni A; Häussinger D; Luedde T; Münk C
Virology; 2021 May; 557():1-14. PubMed ID: 33581610
[TBL] [Abstract][Full Text] [Related]
33. APOBEC3A Is Upregulated by Human Cytomegalovirus (HCMV) in the Maternal-Fetal Interface, Acting as an Innate Anti-HCMV Effector.
Weisblum Y; Oiknine-Djian E; Zakay-Rones Z; Vorontsov O; Haimov-Kochman R; Nevo Y; Stockheim D; Yagel S; Panet A; Wolf DG
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956761
[TBL] [Abstract][Full Text] [Related]
34. Visualization of uracils created by APOBEC3A using UdgX shows colocalization with RPA at stalled replication forks.
Stewart JA; Schauer G; Bhagwat AS
Nucleic Acids Res; 2020 Nov; 48(20):e118. PubMed ID: 33074285
[TBL] [Abstract][Full Text] [Related]
35. Interaction with the CCT chaperonin complex limits APOBEC3A cytidine deaminase cytotoxicity.
Green AM; DeWeerd RA; O'Leary DR; Hansen AR; Hayer KE; Kulej K; Dineen AS; Szeto JH; Garcia BA; Weitzman MD
EMBO Rep; 2021 Sep; 22(9):e52145. PubMed ID: 34347354
[TBL] [Abstract][Full Text] [Related]
36. Stem-loop structure preference for site-specific RNA editing by APOBEC3A and APOBEC3G.
Sharma S; Baysal BE
PeerJ; 2017; 5():e4136. PubMed ID: 29230368
[TBL] [Abstract][Full Text] [Related]
37. Clinical implications of APOBEC3A and 3B expression in patients with breast cancer.
Kim YS; Sun S; Yoon JS; Ko YH; Won HS; Kim JS
PLoS One; 2020; 15(3):e0230261. PubMed ID: 32176735
[TBL] [Abstract][Full Text] [Related]
38. Orthologous mammalian APOBEC3A cytidine deaminases hypermutate nuclear DNA.
Caval V; Suspène R; Vartanian JP; Wain-Hobson S
Mol Biol Evol; 2014 Feb; 31(2):330-40. PubMed ID: 24162735
[TBL] [Abstract][Full Text] [Related]
39. A split cytosine deaminase architecture enables robust inducible base editing.
Long J; Liu N; Tang W; Xie L; Qin F; Zhou L; Tao R; Wang Y; Hu Y; Jiao Y; Li L; Jiang L; Qu J; Chen Q; Yao S
FASEB J; 2021 Dec; 35(12):e22045. PubMed ID: 34797942
[TBL] [Abstract][Full Text] [Related]
40. Dissecting APOBEC3G substrate specificity by nucleoside analog interference.
Rausch JW; Chelico L; Goodman MF; Le Grice SF
J Biol Chem; 2009 Mar; 284(11):7047-58. PubMed ID: 19136562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
